gartisertib   Click here for help

GtoPdb Ligand ID: 11647

Synonyms: M-4344 | M4344 | VX-803 | VX803
Compound class: Synthetic organic
Comment: M4344 (VX-803) is a small molecule, ATP-competitive, selective and orally deliverable inhibitor of the DNA damage response pathway kinase, ataxia telangiectasia and rad3-related (ATR) [1]. The chemical structure of M4344 matches that for gartisertib, which was surfaced in WHO Proposed list 125 in July 2021.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 134.22
Molecular weight 541.24
XLogP -0.11
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1cnc2n(c1)nc(c2C(=O)Nc1cncc(c1N1CCC(CC1)C(=O)N1CCN(CC1)C1COC1)F)N
Isomeric SMILES C1CN(CCC1C(=O)N1CCN(CC1)C1COC1)c1c(cncc1NC(=O)c1c2ncc(cn2nc1N)F)F
InChI InChI=1S/C25H29F2N9O3/c26-16-9-30-23-20(22(28)32-36(23)12-16)24(37)31-19-11-29-10-18(27)21(19)34-3-1-15(2-4-34)25(38)35-7-5-33(6-8-35)17-13-39-14-17/h9-12,15,17H,1-8,13-14H2,(H2,28,32)(H,31,37)
InChI Key QAYHKBLKSXWOEO-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
M4344 is being evaluated for anti-tumourigenic effects in advanced solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04149145 Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer Phase 1 Interventional University of Alabama at Birmingham
NCT02278250 First in Human Study of M4344 in Participants With Advanced Solid Tumors Phase 1 Interventional EMD Serono